Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EPS (Weighted Average and Diluted) (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.16 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 100.0% to -$0.16 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.33, a 312.5% decrease, with the full-year FY2025 number at -$0.34, down 1600.0% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.16 in Q4 2025 for Fennec Pharmaceuticals, down from -$0.02 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.41 in Q1 2024 to a low of -$0.31 in Q3 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.16 (2021), compared with a mean of -$0.13.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 278.26% in 2024, down 200.0% in 2024.
  • Fennec Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.16 in 2021, then crashed by 56.25% to -$0.25 in 2022, then skyrocketed by 60.0% to -$0.1 in 2023, then rose by 20.0% to -$0.08 in 2024, then plummeted by 100.0% to -$0.16 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.16 (Q4 2025), -$0.02 (Q3 2025), and -$0.11 (Q2 2025) per Business Quant data.